The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The gene symbol “CG7159” is ambiguous/historical, and the literature is extremely limited for this specific protein. Using the identity supplied in the query, the correct target is the Drosophila melanogaster locus CG32354, FlyBase FBgn0052354, encoding UniProt Q9VSK1. CG7159, CG17355, CG7027, CK01670, BEST:CK01670, and Dmel\CG32354 are treated here only as aliases attached to that record. Exact searches using Q9VSK1, CG32354, FBgn0052354, and CG7159 retrieved no target-specific primary publication; critically, no literature concerning a similarly named gene in another organism was used.
The most defensible present annotation is therefore “Kazal-like domain-containing protein.” Its primary molecular activity, target protease, substrate specificity, cellular location, biological pathway, and in-vivo role have not been experimentally established in the literature retrieved. A role as a secreted or extracellular serine-protease inhibitor is biologically plausible from the Kazal-domain annotation, but it remains a hypothesis—not a demonstrated function.
| Annotation question | Best-supported conclusion | Evidence type/strength | What remains unknown |
|---|---|---|---|
| Identity | Q9VSK1 corresponds to a Drosophila melanogaster Kazal-like domain-containing protein at the CG32354/FBgn0052354 locus; CG7159, CG17355, CG7027, CK01670, and BEST:CK01670 are supplied historical synonyms. | Strong identity evidence: user-supplied UniProt record and cross-references; exact-identifier searches found no conflicting protein. | Whether every historical alias remains valid in current genome annotations; gene-specific literature is absent from the retrieved corpus. |
| Domain architecture | The supplied annotation includes Kazal_dom (IPR002350), Kazal_dom_sf (IPR036058), Prot_Inhib_GrowthFact_Antg (IPR050653), Kazal_1 (PF00050), and Kazal_2 (PF07648). | Moderate computational evidence: user-supplied InterPro/Pfam/PROSITE annotations; not experimental domain characterization. | Exact domain boundaries, disulfide connectivity, reactive-loop sequence, processing, and whether each predicted module is folded and active. |
| Primary molecular function | The defensible annotation is Kazal-like domain-containing protein. Protease inhibition is plausible because characterized Kazal modules can bind proteases through a reactive loop, but it is not demonstrated for Q9VSK1 (lavergne2021tissuefactorpathway pages 4-6, lavergne2021tissuefactorpathway pages 2-4). | Hypothesis only for Q9VSK1: comparative biochemical/structural evidence from unrelated Kazal proteins. | Whether Q9VSK1 inhibits any protease, has a non-inhibitory binding role, or performs another function. |
| Substrate or target specificity | No target protease or substrate is known for Q9VSK1. Related Kazal inhibitors can be highly selective; one comparator inhibited KLK12 with a reported Kᵢ of 3.0 nM but did not inhibit several other kallikreins (lavergne2021tissuefactorpathway pages 2-4). | No gene-specific evidence; strong comparator evidence only. The numerical value must not be transferred to Q9VSK1. | Target protease class, cleavage specificity, reactive-site P1 residue, affinity, stoichiometry, and physiological substrate network. |
| Localization | Localization is unestablished. Extracellular action is biologically plausible for a disulfide-stabilized Kazal protein, because characterized family members can function in extracellular matrix or apoplastic compartments (lavergne2021tissuefactorpathway pages 4-6, wang2021cleavageofa pages 25-28, wang2021cleavageofa pages 1-5). | Weak inference: comparative family evidence; no Q9VSK1 localization experiment or validated secretion evidence was retrieved. | Signal-peptide functionality, secretion, membrane association, tissue compartment, extracellular-matrix binding, and developmental or cell-type localization. |
| Pathways and biological processes | No pathway can be assigned confidently. Comparative Kazal proteins regulate extracellular proteolysis, matrix remodeling, pro-protein activation, or host–pathogen interactions, but these examples involve unrelated proteins (lavergne2021tissuefactorpathway pages 4-6, wang2021cleavageofa pages 25-28, wang2021cleavageofa pages 1-5). | Unproven comparative hypothesis. | Whether CG32354 participates in development, immunity, reproduction, digestion, tissue remodeling, or another process in Drosophila. |
| Gene-specific experiments | Exact searches for Q9VSK1, CG32354, FBgn0052354, and CG7159 retrieved no direct primary study. No validated enzyme assay, interaction, knockout phenotype, rescue, imaging, or targeted expression result was identified. | Evidence gap: absence in the retrieved literature, not proof that no data exist anywhere. | All direct functional, genetic, biochemical, structural, and localization evidence. |
| Recent 2023–2024 research | No 2023–2024 study directly addressing CG32354/Q9VSK1 was retrieved. Recent Kazal literature found by broader searches concerns other organisms and proteins and therefore cannot establish this fly protein’s function. | No target-specific recent evidence. | Whether unpublished datasets or newly curated high-throughput resources contain informative CG32354 results. |
| Applications | No diagnostic, therapeutic, agricultural, industrial, or other real-world implementation of CG32354/Q9VSK1 was identified. Related Kazal inhibitors are investigated as modulators of protease-driven processes, but that translational context is not evidence for this protein (lavergne2021tissuefactorpathway pages 4-6). | None demonstrated for the target. | Whether recombinant Q9VSK1 has useful inhibitory activity, stability, selectivity, or research-tool potential. |
Table: This table separates verified identity and computational domain annotations for Q9VSK1 from hypotheses based on unrelated Kazal proteins. It highlights the substantial gene-specific evidence gaps that prevent confident assignment of activity, localization, pathway, or application.
The supplied UniProt record identifies Q9VSK1 as a protein from DROME, Drosophila melanogaster, with the recommended description “Kazal-like domain-containing protein.” The supplied cross-references connect it to CG32354/FBgn0052354, while CG7159 and the other CG/CK names represent historical annotation aliases. The domain calls—InterPro Kazal_dom (IPR002350), Kazal_dom_sf (IPR036058), Prot_Inhib_GrowthFact_Antg (IPR050653), and Pfam Kazal_1/Kazal_2—are internally consistent with that description.
This establishes correspondence among the supplied identifiers but does not establish biochemical function. In particular, a domain database match is not equivalent to a demonstrated protease-inhibition assay, validated substrate, or physiological pathway.
Authoritative record URLs are:
Database pages are continuously updated resources rather than conventional dated primary publications; their current records should be checked before experimental design.
There is presently no evidence sufficient to classify Q9VSK1 as an enzyme, transporter, structural protein, signaling ligand, or experimentally verified protease inhibitor. No catalytic reaction should be assigned. No target protease or physiological substrate is known. The safe functional name remains “Kazal-like domain-containing protein.”
Canonical inhibitory Kazal modules are compact, disulfide-stabilized interaction domains that can engage a protease through an exposed reactive-site loop. The residue occupying the P1 position and surrounding loop contacts are major determinants of which proteases are inhibited. Consequently, even proteins sharing a Kazal fold may differ greatly in target spectrum and affinity.
A biochemical comparator illustrates this specificity. In human TFPI-2, an inhibitory domain places P1 Arg15 at the protease interface and inhibits KLK12 with a reported Ki of 3.0 nM and plasmin with a Ki of 1.7 nM, while several other kallikreins were not inhibited. These values characterize TFPI-2—not Q9VSK1—and demonstrate why target specificity cannot be inferred merely from a Kazal-domain call. Lavergne et al., published May 2021, DOI: https://doi.org/10.1515/hsz-2020-0389 (lavergne2021tissuefactorpathway pages 2-4)
Thus, the leading testable hypothesis is that Q9VSK1 binds and possibly inhibits one or more proteases. However, the following alternatives remain open:
No substrate specificity is known for Q9VSK1. For a protease inhibitor, it is more precise to identify the target protease and inhibited proteolytic reaction than to call the inhibitor’s partner a conventional substrate. Those data are absent here.
Related Kazal inhibitors can be selective at the level of protease family members. TFPI-2 inhibited KLK12 and strongly inhibited KLK5 but did not inhibit KLK1, KLK7, KLK8, or KLK14 in the cited study. Structural interpretation implicated reactive-loop and electrostatic contacts, demonstrating that domain membership alone does not determine specificity (lavergne2021tissuefactorpathway pages 4-6, lavergne2021tissuefactorpathway pages 2-4).
For Q9VSK1, defensible annotation requires recombinant-protein assays against a panel of Drosophila trypsin-like, chymotrypsin-like, subtilisin-like, and other plausible extracellular proteases. Reactive-loop mutagenesis would then test whether inhibition uses a canonical Kazal mechanism.
No experimentally verified Q9VSK1 localization was retrieved. Therefore, assignment to the extracellular space, plasma membrane, secretory pathway, or a particular tissue would be premature.
Extracellular localization is nevertheless a reasonable hypothesis because many characterized Kazal inhibitors regulate secreted proteases in oxidizing environments compatible with disulfide-stabilized folding. For example, Phytophthora infestans EPI1 acts in the plant apoplast, where it inhibits tomato P69B-like subtilases and suppresses protease-dependent generation of an immunogenic peptide. This establishes a possible extracellular operating mode for a Kazal inhibitor, not the localization of the fly protein. Wang et al., published January 2021, DOI: https://doi.org/10.1111/nph.17120 (wang2021cleavageofa pages 25-28, wang2021cleavageofa pages 1-5)
The highest-priority localization checks are therefore: sequence-based signal-peptide and transmembrane-segment analysis; secretion assays using tagged protein; extracellular-medium proteomics; and endogenous imaging with a validated knock-in tag. A predicted signal peptide, if present, would support but still not prove secretion.
No named Drosophila signaling or biochemical pathway can presently be assigned to CG32354 with confidence. There is no retrieved direct evidence connecting it to Toll, Imd, melanization, developmental patterning, reproduction, digestion, extracellular-matrix remodeling, or another defined fly pathway.
Comparative Kazal biology suggests several hypothesis classes:
These are possibilities only. In the TFPI-2 comparator, protease inhibition blocked KLK12-mediated proMMP-1 activation, reduced proMMP-3 activation, and prevented cleavage of extracellular-matrix-associated CCN1 at 20 nM inhibitor. This is strong evidence that a characterized inhibitor can regulate extracellular proteolytic networks, but it cannot be transferred as a pathway annotation to CG32354 (lavergne2021tissuefactorpathway pages 4-6).
The retrieved literature contains zero target-specific mechanistic studies identified by the supplied stable or historical identifiers. Accordingly, no Q9VSK1-specific values are available for inhibition constants, catalytic rates, binding affinities, expression fold changes, phenotype penetrance, or localization fractions.
Quantitative family comparators include:
These statistics demonstrate the kinds of measurements needed for Q9VSK1; they are not estimates of Q9VSK1 activity.
No 2023–2024 publication directly studying CG32354/Q9VSK1 was found. Broader recent searches retrieved Kazal research involving unrelated human and arthropod proteins, including clinical skin-barrier biology and mosquito salivary proteins, but these do not resolve the function of the Drosophila target. The current research frontier for this gene is therefore basic annotation rather than refinement of an established mechanism.
This negative result is scientifically important: assigning a specific target, pathway, or localization from recent studies of SPINK proteins, LEKTI, mosquito anticoagulants, or pathogen Kazal inhibitors would conflate non-orthologous proteins and violate the identity constraint in the question.
No diagnostic, therapeutic, agricultural, industrial, or established research-tool application of CG32354/Q9VSK1 was identified. Kazal-family inhibitors in other systems are being explored as modulators of protease-dependent matrix remodeling, inflammation, barrier biology, infection, and envenoming. Such work shows translational potential for the broader molecular class, but no application can presently be claimed for this fly protein.
If Q9VSK1 proves to be a stable, selective inhibitor, possible future uses could include a reagent for dissecting fly protease cascades or a scaffold for inhibitor engineering. These are prospective applications contingent on biochemical validation.
CG32354/CG7159 encodes a computationally predicted Kazal-like domain-containing protein in Drosophila melanogaster. A protease-regulatory function is plausible from domain homology, but inhibitory activity, target specificity, localization, and physiological pathway remain unverified.
Q9VSK1 should not yet be called a specific serine-protease inhibitor. The Kazal-domain architecture makes that the strongest mechanistic hypothesis, especially for an extracellular protease-regulatory role, but current evidence does not identify a target, inhibited reaction, compartment, or pathway. The correct research conclusion is therefore an explicitly qualified, domain-based annotation coupled to targeted biochemical and genetic validation—not transfer of function from better-characterized Kazal proteins in other organisms.
References
(lavergne2021tissuefactorpathway pages 4-6): Marion Lavergne, Audrey Guillon-Munos, Woodys Lenga Ma Bonda, Sylvie Attucci, Thomas Kryza, Aurélia Barascu, Thierry Moreau, Agnès Petit-Courty, Damien Sizaret, Yves Courty, Sophie Iochmann, and Pascale Reverdiau. Tissue factor pathway inhibitor 2 is a potent kallikrein-related protease 12 inhibitor. May 2021. URL: https://doi.org/10.1515/hsz-2020-0389, doi:10.1515/hsz-2020-0389. This article has 14 citations and is from a peer-reviewed journal.
(lavergne2021tissuefactorpathway pages 2-4): Marion Lavergne, Audrey Guillon-Munos, Woodys Lenga Ma Bonda, Sylvie Attucci, Thomas Kryza, Aurélia Barascu, Thierry Moreau, Agnès Petit-Courty, Damien Sizaret, Yves Courty, Sophie Iochmann, and Pascale Reverdiau. Tissue factor pathway inhibitor 2 is a potent kallikrein-related protease 12 inhibitor. May 2021. URL: https://doi.org/10.1515/hsz-2020-0389, doi:10.1515/hsz-2020-0389. This article has 14 citations and is from a peer-reviewed journal.
(wang2021cleavageofa pages 25-28): Shuaishuai Wang, Rongkang Xing, Yan Wang, Haidong Shu, Shenggui Fu, Jie Huang, Judith K. Paulus, Mariana Schuster, Diane G. O. Saunders, Joe Win, Vivianne Vleeshouwers, Yuanchao Wang, Xiaobo Zheng, Renier A.L. van der Hoorn, and Suomeng Dong. Cleavage of a pathogen apoplastic protein by plant subtilases activates host immunity. Jan 2021. URL: https://doi.org/10.1111/nph.17120, doi:10.1111/nph.17120. This article has 54 citations and is from a highest quality peer-reviewed journal.
(wang2021cleavageofa pages 1-5): Shuaishuai Wang, Rongkang Xing, Yan Wang, Haidong Shu, Shenggui Fu, Jie Huang, Judith K. Paulus, Mariana Schuster, Diane G. O. Saunders, Joe Win, Vivianne Vleeshouwers, Yuanchao Wang, Xiaobo Zheng, Renier A.L. van der Hoorn, and Suomeng Dong. Cleavage of a pathogen apoplastic protein by plant subtilases activates host immunity. Jan 2021. URL: https://doi.org/10.1111/nph.17120, doi:10.1111/nph.17120. This article has 54 citations and is from a highest quality peer-reviewed journal.